Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keryx Licenses Japanese Rights For Zerenex To Japan Tobacco In $100 Million Deal

This article was originally published in PharmAsia News

Executive Summary

Keryx Biopharmaceuticals got a major boost Sept. 26 in its effort to bring the Phase II hyperphosphatemia candidate Zerenex to the worldwide market by signing a licensing agreement potentially worth up to $100 million with Japan Tobacco and its subsidiary, Torii Pharmaceutical

You may also be interested in...

Genzyme Gets Mixed Results On Renvela Powder Formulation

An NDA for the tablet form of the follow-on chronic kidney disease therapy is pending at FDA.

Amgen Gains Phase II Phosphate Binder With Acquisition of Ilypsa

Ilypsa’s lead candidate, ILY1001, for treatment of hyperphosphatemia in chronic kidney disease, complements Amgen’s anemia agents.

Keryx Looks To Release Top-Line Sulonex Phase III Data Early Next Year

A 2008 launch of the first-in-class diabetic nephropathy treatment is possible.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts